Freenome, Inc. Common stock
FRNM
NASDAQ11.24
USD
-0.96
- -
CIK
0001676446
ISIN
US35661P1003
CUSIP
35661P100
Return %
Stock
S&P500
1Y
2.09
15.98
3Y
2.09
62.25
5Y
2.09
67.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Adam Leo Stone
- Full Time Employees
- 3
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Address
- 259 E Grand Avenue New York NY United States of America 94080
- IPO Date
- Jul 21, 2026
- CIK
- 0001676446
- Website
- perceptivelife.com
- Similar Companies
- Business
- Freenome, Inc. Common stock (FRNM) operates as a biotechnology company focused on oncology diagnostics and related services, leveraging multi-omics assays to detect cancer and monitor disease. The company develops and commercializes tools that integrate genomic, proteomic, and clinical data to enable early cancer detection, precision monitoring, and therapeutic decision support, targeting clinical laboratories, healthcare providers, and researchers. Freenome positions itself as a data-driven platform company that combines wet-lab capabilities with AI-powered analytics to generate actionable biomarkers and diagnostic insights. Main products and services - Multi-omics cancer detection assays: leveraging genomics, proteomics, and clinical data to identify cancer-associated biomarkers and generate non-invasive diagnostic results; includes in vitro diagnostic offerings intended for screening and early detection contexts - AI-driven biomarker discovery and analytics platform: cloud-based and on-premises computational tools that integrate heterogeneous data to identify signatures associated with cancer risk, progression, and response to therapy - Laboratory services and processing capabilities: sample processing, sequencing, and assay development services for partners and customers requiring bespoke or validation workflows - Companion diagnostics and assay development partnerships: collaboration services to co-develop and validate tests aligned with specific therapeutic areas or regulatory pathways - Data collaboration and research services: access to large-scale datasets, analytic pipelines, and research support for academic and industry researchers exploring oncologic biomarker discovery Latest major company changes - Strategic partnerships and alliances: formation of collaborations with biopharma, diagnostics developers, and clinical partners to co-develop and validate cancer diagnostics and companion tests - Funding rounds and potential corporate actions: recent equity financing and potential strategic investments to advance platform capabilities, expand assay development, and scale commercialization efforts; corporate activity associated with pursuing broader market access - New product launches and service expansions: introductions or updates to multi-omics tests and analytics offerings; expansion of services to support broader clinical validation and real-world evidence generation - Business expansion and organizational changes: scaling of operational footprint to support increased clinical study activity, manufacturing validation, and data platform enhancements - Corporate restructurings or name changes: notable reorganizations to streamline product focus and align with strategic partnerships and market opportunities Note: Specific deal names, amounts, and dates are subject to public disclosure and may require verification from primary filings and corporate announcements Industry context and business segments - Industry: biotechnology, diagnostics, precision medicine, and AI-enabled healthcare analytics - Business segments: oncology diagnostics development, bioinformatics platforms, laboratory services, and research collaborations - Target markets: clinical laboratories, healthcare providers, pharmaceutical and biotechnology companies, academic and research institutions - Geographic operations: United States at minimum, with potential export or international collaboration activity; distribution and collaboration partnerships may extend to Europe and other regions depending on regulatory approvals and service scope Founding year and headquarters - Founding year: not publicly disclosed in accessible public sources - Headquarters: not publicly disclosed in accessible public sources Subsidiaries and parent relationships - Freenome operates as an independent biotechnology entity pursuing internal and collaborative development programs; specific subsidiary relationships or parent company ties are not detailed in publicly available information Notes - Information is based on publicly available sources and may reflect interim corporate activity and roadmap updates; verify current corporate status, regulatory approvals, and fiscal details from official filings and company communications for the most up-to-date accuracy.